Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Advertisement
Advertisement
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
United States District Judge Sean D. Jordan entered the final judgment to vacate a new FDA regulation regarding lab tests.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Machine learning may aid point-of-care clinical decision-making for NHL patients receiving CAR T-cell therapy.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
A compound to assist CAR T-cell therapy by targeting and suppressing YTHDF2 is in development.
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
A new study aimed to confirm the possible synergy between loncastuximab and rituximab.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Swetha Kambhampati, MDAssistant Professor, Division of Lymphoma | City of Hope Comprehensive Cancer Center
Advertisement
Latest News
Section Editor
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.